Crispr Therapeutics shares tumble after significant earnings miss
Chief Operating Officer Tan Kwang Hooi of Flex Ltd (NASDAQ:FLEX) sold 12,500 ordinary shares of the company on July 28, 2025, for approximately $628,102. Prices for the shares sold ranged from $49.92 to $50.68. The transaction comes as Flex shares trade near their 52-week high of $53.97, having delivered an impressive 58.72% return over the past year. According to InvestingPro analysis, the stock appears fairly valued at current levels.
Following the transaction, Tan Kwang Hooi directly owns 263,636 Flex Ltd. shares, including unvested restricted share units (RSUs) that will vest in the coming years. With a market capitalization of $18.85 billion, Flex has shown strong momentum, and InvestingPro data reveals that management has been actively buying back shares. Discover 10+ additional exclusive insights available on InvestingPro.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
In other recent news, Flextronics reported its first-quarter earnings for fiscal year 2026, delivering an adjusted earnings per share (EPS) of $0.72, which exceeded analyst expectations of $0.63. The company’s revenue reached $6.6 billion, surpassing the forecasted $6.26 billion. Despite these strong financial results, Flextronics’ stock experienced a decline in pre-market trading. Additionally, the company raised its revenue guidance to $26.5 billion from the previous $25.9 billion. KeyBanc Capital Markets maintained its Overweight rating on Flextronics, with a price target of $60.00, viewing the recent 7.7% sell-off as a buying opportunity. The research firm noted that investor concerns were primarily due to the maintained operating margin guidance of 6.0-6.1%, despite the higher revenue outlook. These developments highlight the mixed reactions from the market and analysts to Flextronics’ recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.